“`html
Kewaunee Scientific Corporation (KEQU) reported first-quarter fiscal 2026 results on July 31, 2025, showing a 46.9% increase in sales to $71.1 million compared to $48.4 million a year prior. Despite a net earnings rise of 41.1% to $3.1 million, shares have declined 19.7% since the earnings report, contrasting with a 0.4% rise in the S&P 500 during the same period. Over the past month, Kewaunee’s stock is down 23.8%.
Domestic sales surged 53% to $54.4 million, while international sales increased 30.2% to $16.8 million. The company’s order backlog was $205 million, up from $159.4 million a year earlier. Management anticipates uneven quarterly performance for fiscal 2026 due to project delivery volatility, despite expressing confidence in long-term growth driven by strategic investments and the recent acquisition of Nu Aire, Inc.
As of the end of July, Kewaunee had total cash of $20.4 million and improved debt metrics, with short-term debt decreasing to $4.3 million. Management reported a pre-tax net loss of $3.1 million in the corporate segment, which impacted overall results.
“`
